$14.73
4.25% today
NYSE, Apr 02, 09:20 pm CET
ISIN
US68622V1061
Symbol
OGN

Organon & Co. Stock price

$14.13
-0.22 1.53% 1M
-4.70 24.96% 6M
-0.79 5.29% YTD
-4.37 23.62% 1Y
-21.02 59.80% 3Y
-19.12 57.50% 5Y
-19.12 57.50% 10Y
NYSE, Closing price Tue, Apr 01 2025
-0.76 5.10%
ISIN
US68622V1061
Symbol
OGN
Sector
Industry

Key metrics

Market capitalization $3.64b
Enterprise Value $12.01b
P/E (TTM) P/E ratio 4.24
EV/FCF (TTM) EV/FCF 15.71
EV/Sales (TTM) EV/Sales 1.88
P/S ratio (TTM) P/S ratio 0.57
P/B ratio (TTM) P/B ratio 7.72
Dividend yield 7.93%
Last dividend (FY24) $1.12
Revenue growth (TTM) Revenue growth 2.24%
Revenue (TTM) Revenue $6.40b
EBIT (operating result TTM) EBIT $1.49b
Free Cash Flow (TTM) Free Cash Flow $764.00m
Cash position $675.00m
EPS (TTM) EPS $3.33
P/E forward 3.79
P/S forward 0.58
EV/Sales forward 1.91
Short interest 9.49%
Show more

Is Organon & Co. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Organon & Co. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Organon & Co. forecast:

3x Buy
33%
4x Hold
44%
2x Sell
22%

Analyst Opinions

9 Analysts have issued a Organon & Co. forecast:

Buy
33%
Hold
44%
Sell
22%

Financial data from Organon & Co.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
6,403 6,403
2% 2%
100%
- Direct Costs 2,688 2,688
7% 7%
42%
3,715 3,715
1% 1%
58%
- Selling and Administrative Expenses 1,476 1,476
11% 11%
23%
- Research and Development Expense 469 469
11% 11%
7%
1,770 1,770
13% 13%
28%
- Depreciation and Amortization 276 276
17% 17%
4%
EBIT (Operating Income) EBIT 1,494 1,494
13% 13%
23%
Net Profit 864 864
16% 16%
13%

In millions USD.

Don't miss a Thing! We will send you all news about Organon & Co. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Organon & Co. Stock News

Neutral
Business Wire
one day ago
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announced it has acquired regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion.
Neutral
Business Wire
5 days ago
SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)--Henlius and Organon announced the European Medicines Agency validates filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11.
Positive
Seeking Alpha
16 days ago
In mid-February, Organon pleasantly surprised me with its financial results for the fourth quarter of 2024. So, sales of Hadlima, a biosimilar to Humira, amounted to $44 million in the last three months of 2024, an increase of 83.3% year-on-year. Organon's dividend yield is 7.32%, which is significantly higher than that of the healthcare sector.
More Organon & Co. News

Company Profile

Organon & Co. is a science based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020 and is headquartered in Jersey City, NJ.

Head office United States
CEO Kevin Ali
Employees 10,000
Founded 2020
Website www.organon.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today